media – Page 664 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Novartis bags first-line approval for Zykadia

The European Commission has expanded the scope of Novartis’ Zykadia to include the first line treatment of patients with non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.
- Source: pharmatimes
- 502
- June 30, 2017
cancer Company Insight New Approvals NSCLC Zykadia
Beta blockers may protect against heart failure

In a study conducted at York University, scientists came to the astonishing conclusion that beta blockers could protect against heart failure. This was one of the latest discoveries in a field with endless treatments managing symptoms though previously damage sustained to the heart can’t be revered.
- Source: Ddu
- 438
- June 30, 2017
beta blocker heart mortality New Approvals
FDA approval granted to Emmaus for sickle cell therapy

Emmaus Medical recently received FDA (The U.S. Food and Drug Administration) approval for sickle cell disease therapy Endari (L-gluitamine), ending two decades of drought for treatment of the disease and giving an alternative to the only other drug on the market, hydroxyurea.
- Source: Ddu
- 509
- June 29, 2017
Endari FDA formulation New Approvals
LifeArc teams up with UK defence lab and Canada’s CDRD

LifeArc, the UK medical research charity previously known as MRC Technology, is working alongside the government’s Defence Science and Technology Laboratory and Canada’s Centre for Drug Research and Development (CDRD) to identify new antibacterial drug targets.
- Source: pharmatimes
- 601
- June 29, 2017
antibacterial LifeArc Market Views Researches
GSK tests mepolizumab for nasal polyps

GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
- Source: Pharmtimes
- 814
- June 28, 2017
Clinical Trials EU mepolizumab
GSK tests mepolizumab for nasal polyps

GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
- Source: pharmatimes
- 791
- June 28, 2017
asthma Company Insight EU surgery
EU regulators reviewing Shire’s bleeding disorder drug

European regulators have validated the marketing authorisation application for Shire’s experimental von Willebrand Disease therapy Veyvondi.
- Source: pharmatimes
- 615
- June 26, 2017
EU FDA genetic therapy
Drugdu.com (Ddu) attended CPhI China 2017 for new pharmaceutical industry pattern

CPhI China 2017 was held at the Shanghai New International Expo Center from June 20 to 22. As the leading global pharmaceuticals and medical devices industry platform, Ddu presented a wide range of services which connect the traditional medical industry with the Internet including one-stop service solutions, buying offer sharing of global exhibitions, credit verification and so forth.
- Source: Ddu
- 946
- June 24, 2017
App buying offers CPhI Exhibitions & Activities
Global Hemodialysis Consumables Market Analysis

As the most potential market in china, Hemodialysis market appears a large revenue space. With the opening of private hemodialysis services, private economy in the hemodialysis industry is about to take a ”Golden era”.
- Source: Ddu
- 600
- June 24, 2017
hemodialysis consumables Market Reports
US nod for CSL Behring’s HAE prevention therapy

US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary (HAE) attacks in adolescent and adults.
- Source: pharmatimes
- 441
- June 23, 2017
HAE inhibitor New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.